US 11,986,446 B2
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mark Eller, Redwood City, CA (US)
Assigned to Jazz Pharmaceuticals Ireland Limited, Dublin (IE)
Filed by Jazz Pharmaceuticals Ireland Limited, Dublin (IE)
Filed on Dec. 27, 2021, as Appl. No. 17/562,787.
Application 17/562,787 is a continuation of application No. 17/216,540, filed on Mar. 29, 2021, granted, now 11,253,494.
Application 17/216,540 is a continuation of application No. 17/094,778, filed on Nov. 10, 2020, abandoned.
Application 17/094,778 is a continuation of application No. 16/245,067, filed on Jan. 10, 2019, granted, now 10,864,181, issued on Dec. 15, 2020.
Application 16/245,067 is a continuation of application No. 15/869,792, filed on Jan. 12, 2018, granted, now 10,213,400, issued on Feb. 26, 2019.
Application 15/869,792 is a continuation of application No. 15/343,806, filed on Nov. 4, 2016, abandoned.
Application 15/343,806 is a continuation of application No. 14/707,914, filed on May 8, 2015, granted, now 9,486,426, issued on Nov. 8, 2016.
Application 14/707,914 is a continuation of application No. 13/837,714, filed on Mar. 15, 2013, granted, now 9,050,302, issued on Jun. 9, 2015.
Claims priority of provisional application 61/777,873, filed on Mar. 12, 2013.
Claims priority of provisional application 61/771,557, filed on Mar. 1, 2013.
Prior Publication US 2022/0193015 A1, Jun. 23, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/19 (2006.01); A61K 31/20 (2006.01); A61K 31/33 (2006.01); A61K 31/505 (2006.01); A61K 31/55 (2006.01); A61K 31/616 (2006.01); A61P 11/00 (2006.01); A61P 25/20 (2006.01); A61P 43/00 (2006.01); G16H 20/10 (2018.01)
CPC A61K 31/19 (2013.01) [A61K 31/20 (2013.01); A61K 31/33 (2013.01); A61K 31/505 (2013.01); A61K 31/55 (2013.01); A61K 31/616 (2013.01); A61P 11/00 (2018.01); A61P 25/20 (2018.01); A61P 43/00 (2018.01); G16H 20/10 (2018.01)] 31 Claims
 
1. A method for the treatment of a patient suffering from cataplexy in narcolepsy or excessive daytime sleepiness, the method comprising: administering a reduced daily dosage amount of gamma-hydroxybutyrate (GHB), a prodrug, or a salt thereof, to the patient; wherein the patient is concomitantly administered divalproex sodium; wherein the daily dosage amount of GHB, prodrug, or salt thereof, is reduced to compensate for pharmacokinetic (PK) and/or pharmacodynamic (PD) changes caused by the concomitant administration of divalproex sodium.